Clinical Aspect of MicroRNA in Lung Cancer

Hye Cheol Jeong, M.D., Ph.D.
Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, CHA Bundang Medical Center, CHA University College of Medicine, Seongnam, Korea

MicroRNAs (miRNAs) are a class of small noncoding RNAs that modulate target gene activity, and are aberrantly expressed in most types of cancer as well in lung cancer. A miRNA can potentially target a diverse set of mRNAs; further, it plays a critical role in lung tumorigenesis as well as affects patient outcome. Previous studies focused mainly on abnormal miRNAs expressions in lung cancer tissues. Interestingly, circulating miRNAs were identified in human plasma and serum in 2008. Since then, considerable effort has been directed to the study of circulating miRNAs as one of the biomarkers of lung cancer. miRNAs expression of tissues and blood in lung cancer patients is being analyzed by more researchers. Recently, to overcome the high false-positivity of low-dose chest computed tomography scan, miRNAs in lung cancer screening are being investigated. This article summarizes the recent researches regarding clinical applications of miRNAs in the diagnosis and management of lung cancer.

Keywords: MicroRNAs; Lung Neoplasms; Biological Markers

Introduction

Technological advances have enhanced the diagnosis and treatment of lung cancer, but the mortality is still high. Lung cancer is hardly detected at early curable stage and there is lack of effective antitumor agents that induce few adverse effects, except for some target therapies. What we need is developing a hematologic marker for lung cancer and a more effective therapy than conventional ones. Efforts are being made to achieve these goals and studies using microRNA (miRNA) have gained a lot of attention recently, ranging from those on basic pathogenesis to those on actual clinical applications. This study was aimed at investigating how far those miRNA researches have progressed with regard to lung cancer and how useful miRNA is in clinical practice.

MicroRNA

miRNA is a single-stranded non-coding RNA molecule, containing 18–25 nucleotides, and is responsible for the expression of various genes in eukaryotes. It has been reported that it is involved in controlling various functions, such as cell development, differentiation, proliferation, cell death, stress reaction, fat metabolism, insulin secretion and carcinogenesis. miRNA combines complementarily with 3′ untranslated region (3′ UTR) of target genes to control those target genes by inhibiting mRNA translation. Single miRNA may affect multiple miRNAs or multiple miRNAs may affect single mRNA. It is well known that miRNA is involved in a lot of biological processes of normal cells, and accumulating data suggests expression of abnormal miRNAs in many diseases. The process of miRNA biogenesis is presented in Figure 1.

Details of the biogenesis process are not discussed here in order to focus on clinical features of miRNA.
MicroRNA and Cancer

It has been reported that abnormal miRNAs are also detected in hematologic malignancies and solid cancers. For example, miR-15 and miR-16 combine with B cell lymphoma 2 (BCL2) to induce apoptosis in normal cells but their expression is reduced in malignant lymphoma, possibly because cell apoptosis is inhibited by abnormal expression of miRNAs. In addition, miRNA is thought to be closely associated with signaling in cancer development and cancer metastasis. With studies revealing interactions between miRNA and previously known cancer genes, recent data suggests the role of miRNA in cancer stem cells.

MicroRNA and Lung Cancer

Abnormal expression of miRNA in lung cancer has been researched since 2004, demonstrating interaction between miRNA and various lung cancer-related genes (Table 1). One example is the interaction between RAS and p53 genes and the expression of miRNAs. RAS mutation (K-RAS, especially) is clinically important in lung cancer and the let-7 family of miRNAs is known to regulate RAS expression. In 2005, Johnson et al. reported that let-7 regulated *Caenorhabditis elegans* let-60 gene (the ortholog of human RAS) and that 3′ UTR of human RAS gene had a lot of let-7 complimentary sites. They confirmed that RAS expression was increased when let-7 was inhibited in normal lung epithelial cell. In tumor tissues from lung cancer, let-7 was reduced at the same time when RAS expression was increased. Researches later found associations between various miRNAs, including miR-451, and RAS gene. There have been studies about miRNAs which is related to p53, a representative tumor suppressor. According to results from studies using a lung cancer stem cell (H1299), p53 increased the expression of miR-34a, inhibiting the proliferation of lung cancer cells and facilitating apoptosis. There is evidence supporting the association between p53 and various miRNAs, including miR-125a. Accumulating data also suggests complex interactions between a lot of cancer genes and signaling molecules.

Clinical Significance of MicroRNA Expression in Lung Cancer

A number of studies have reported miRNA detection in tumor tissue as a diagnostic and prognostic indicator of cancer. Results so far have been promising, although there is some controversy over its prognostic value. With recent identification of circulating ones, miRNA is considered as a possible noninvasive tumor marker. It is clinically promising as a tumor marker because it is stable in patient's tissues or fluids, unlike typical RNAs. miRNA is stably detected in frozen tissues as well as in formalin fixed paraffin embedded tissues, serum, sputum and pleural effusion, mostly by means of microarray
or quantitative reverse transcriptase polymerase chain reaction. The short sequence is also beneficial for lowering the cost of analysis.

Earlier studies had used tumor tissues from lung cancer and normal lung tissues, but the identification of circulating miRNA has made later studies using body fluids (blood, sputum, pleural effusion, etc.) as well tissues in lung cancer patients. Several researchers found diverse miRNAs being detected in a stable way, but most of the studies were retrospective, and further results are required before using them for routine diagnosis. The association between abnormal expression of miRNA and lung cancer was first reported in 2004. Takamizawa et al. measured the level of let-7 expression in normal and tumor tissues from surgically removed lungs in lung cancer patients and found that the expression of let-7 was reduced in tumor tissues compared to that in adjacent normal lung tissues. The survival was shorter in patients with relatively lower level of let-7. Multivariate analysis showed this prognostic impact to be independent of disease stage, age, sex and smoking status. Researches later found miRNAs in various types of patients and attempted to determine its clinical significance. For example, miR-22 expression varied among patients with progressive lung cancer according to their response to pemetrexed therapy. A study even suggested that the genetic polymorphism of a specific miRNA was a prognostic marker. More studies are expected to contribute to the data on miRNA in a similar way. miRNAs have been detected in pleural effusion as well as in

| MicroRNA | Target/Function | Clinical value |
|----------|----------------|----------------|
| Let-7 family | HMGA2, RAS, Myc, cell division | Associated with cancer-specific mortality and disease-free survival; increased sensibility to radiation; elevated postoperative risk of death; rs712GG genotyping in K-RAS 3′-UTR associated with increased risk of NSCLC |
| Let-7a-2 |  | Poor survival in AC patients |
| miR-17 | Cell proliferation | Associated with tumor stage, cancer-specific mortality, and disease-free survival in NSCLC |
| miR-102 |  | Higher levels in AC than in SqCC |
| miR-125a-3p/5p | VEGF | Associated with tumor invasion and lymph node metastasis |
| miR-126 |  | |
| miR-128b | EGFR | Benefit in patients treated with gefitinib |
| miR-145 | c-Myc, elf-4E, CDK4 | |
| miR-155 |  | Associated with tumor stage, cancer-specific mortality, and disease-free survival in NSCLC; able to discriminate lung cancer from healthy donor |
| miR-196a2 |  | rs11614913CC genotype associated with increased risk of lung cancer and reduced overall survival |
| miR-20b |  | Associated with advanced stages and lymph node metastasis |
| miR-21 | K-RAS, cell proliferation | Associated with tumor stage, cancer-specific mortality and disease-free survival in NSCLC; able to discriminate lung cancer from healthy controls |
| miR-29s | DNMT3A, DNMT3B | |
| miR-205 |  | Only detected in SqCC |
| miR-31 | LATS2, PPP2R2A, cell proliferation | |
| miR-328 | Cell migration | Associated with higher risk of brain metastasis development, associated with overall survival |
| miR-451 | RAB14, apoptosis | Associated with NSCLC stage, lymph node metastasis, and poor survival |
| miR-7 | Ets2, cell proliferation | |
| miR-92a-2 |  | Chemoresistance and decreased survival of SCLC cases |
| miR-99b |  | Higher levels in AC than in SqCC |

3′ UTR: 3′ untranslated region; NSCLC: non-small cell lung carcinoma; AC: adenocarcinoma; SqCC: squamous cell carcinoma; VEGF: vascular endothelial growth factor; EGFR: epidermal growth factor receptor; SCLC: small cell lung carcinoma.

Table 1. Lung cancer-related microRNAs
Low-dose chest computed tomography (CT) is currently used for early lung cancer screening among high-risk individuals with smoking history. This strategy was recently found to reduce lung cancer mortality in a large study, but false-positive rate was too high. Recently, it has been suggested that circulating miRNA would be useful for lowering the false-positive rate. Based on high specificity of circulating miRNA for lung cancer, it would be possible to use it as a complement to the low-dose chest CT. One example of this is a large study (MILD trial) that was conducted in Italy since 2005. In addition to assessing the usefulness of low-dose chest CT for lung cancer screening, the investigators also obtained blood samples from the subjects and analyzed them for 24 miRNAs. miRNA analysis alone had 87% sensitivity and 81% specificity for lung cancer diagnosis. Negative predictive value was as high as 99%. On the contrary, the rates were 79%, 81%, and 19.4%, respectively, for low-dose chest CT screening. When low-dose chest CT and miRNA were combined, false positive rate was significantly reduced to 3.7%.

It seems still premature to recognize miRNA as a prognostic factor, because investigators reported conflicting data on the prognostic value of the same miRNA. In a large-scale analysis of samples obtained from International Adjuvant Lung Cancer Trial (IALT), miRNAs that had been found as significant predictors of prognosis (miR-21, miR-29b, miR-31a/b/c, miR-155, and let-7a) were no longer significant. It might be due to the heterogeneity of lung cancer. Lung cancer varies in clinical presentation depending on the histology and genetic mutation. So, specific miRNAs are reported to be expressed differently according to the histology of lung cancer. Results of miRNAs expression may be helpful for histological diagnosis of NSCLC. However, this situation suggests that diverse factors such as histologic subtypes of lung cancer must be considered to predict prognosis with miRNAs. miRNA profile was different between primary cancer and metastatic cancer and between smoker and nonsmoker. Further prospective studies are required in selected population to determine the prognostic value of miRNA.

**MicroRNA and Lung Cancer Screening**

In addition to the attempts to use circulating miRNA as a diagnostic tool, the possibility of using it for early diagnosis has been considered as well. An analysis showed differential expression of serum miRNAs (miR-155, miR-182, and miR-197) between cancer patients and normal population or patients with infectious diseases (pneumonia or tuberculosis). It would be clinically important, therefore, if a miRNA expression before diagnosis or at early stage of cancer could be presented in any way as an evidence of lung cancer. It would be helpful when determining whether or not to perform invasive biopsy if serum miRNA analysis could be used for determining malignancy of solitary pulmonary nodules. Recent studies tend to use statistical software to identify individuals who have a high risk of lung cancer, by conducting a pattern analysis among a large number of miRNAs. In a recent analysis of 34 circulating miRNAs, the diagnostic accuracy of early lung cancer was approximately 80% among asymptomatic high-risk individuals.

miRNA may have a high specificity depending on the tissue or disease, but care should be made before suspecting and making a diagnosis of lung cancer entirely based on miRNA expression. First we need to fill in the gaps in miRNA expression among a wide range of other diseases. One possibility is to consider miRNA as a supplement to conventional tests. Low-dose chest computed tomography (CT) is currently used for early lung cancer screening among high-risk individuals with smoking history. This strategy was recently found to reduce lung cancer mortality in a large study, but false-positive rate was too high. Recently, it has been suggested that circulating miRNA would be useful for lowering the false-positive rate. Based on high specificity of circulating miRNA for lung cancer, it would be possible to use it as a complement to the low-dose chest CT. One example of this is a large study (MILD trial) that was conducted in Italy since 2005. In addition to assessing the usefulness of low-dose chest CT for lung cancer screening, the investigators also obtained blood samples from the subjects and analyzed them for 24 miRNAs. miRNA analysis alone had 87% sensitivity and 81% specificity for lung cancer diagnosis. Negative predictive value was as high as 99%. On the contrary, the rates were 79%, 81%, and 19.4%, respectively, for low-dose chest CT screening. When low-dose chest CT and miRNA were combined, false positive rate was significantly reduced to 3.7%. This is supporting the evidence that miRNA could contribute to the early diagnosis of lung cancer.

Shen et al. found 10 miRNAs which were expressed differently in the sputum of lung cancer patients than in normal individuals. Among them, miR-31 and miR-210 showed 65.2% sensitivity and 89.7% specificity for lung cancer diagnosis. When they were combined with chest CT, specificity was elevated to 91.2%. It is expected that these attempts to use miRNA for early diagnosis of lung cancer in the clinical practice will continue in the future.
controlling such miRNAs. Association between miRNAs (such as let-7 and miR-31) and genes related to radiotherapy sensitivity has been also been proving, most of them being in vitro studies. It is expected that controlling these miRNAs would be useful for increasing the effectiveness of radiotherapy. There is accumulating data suggesting that miRNAs could be used to decrease metastasis, if not to destroy tumors directly, and successful results have been achieved in cancer stem cells. In addition to directly controlling miRNAs, controlling miRNA expression by using new materials and combination with conventional chemotherapies are now being studied as well. More follow-up studies are needed to apply miRNA for treatments in clinical practice.

Conclusions

In lung cancer diagnosis, histological or genetic analysis may be limited by small sample size. Moreover, there is a lack of good biomarkers available for the prediction of prognosis. Low-dose chest CT for early lung cancer screening is limited by high false positive rate and the risk of radiation exposure for general application. In this context, miRNA has been investigated to overcome these issues and some of the studies have reported promising results. It may be still premature to apply miRNA in clinical therapies but it will not be long before it could be used for diagnostic purposes.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Zandberga E, Kozirovskis V, Abols A, Andrejeva D, Purkalne G, Line A. Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Genes Chromosomes Cancer 2013;52:356-69.
2. Leal JA, Lleonart ME. MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Lett 2013;338:174-83.
3. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;126:635-47.
4. Tufman A, Tian F, Huher RM. Can microRNAs improve the management of lung cancer patients? A clinician’s perspective. Theranostics 2013;3:953-63.
5. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6.
6. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13:48-57.
7. Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi GR, Picciotto M, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol 2014;229:979-9.
8. Hu Z, Shu Y, Chen Y, Chen J, Dong J, Liu Y, et al. Genetic polymorphisms in the precursor MicroRNA flanking region and non-small cell lung cancer survival. Am J Respir Crit Care Med 2011;183:641-8.
9. Wang T, Lv M, Shen S, Zhou S, Wang P, Chen Y, et al. Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer. PLoS One 2012;7:e43268.
10. Voortman J,_goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010;70:8288-98.
11. Huang W, Hu J, Yang DW, Fan XT, Jin Y, Hou YY, et al. Two microRNA panels to discriminate three subtypes of lung carcinoma in bronchial brushing specimens. Am J Respir Crit Care Med 2012;186:1160-7.
12. Barshack I, Lithwick-Yanai G, Afek A, Rosenblatt K, Tabibian-Keissar H, Zepeniuk M, et al. MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathol Res Pract 2010;206:578-84.
13. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Hori-kawa I, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 2009;106:12085-90.
14. Abd-El-Fattah AA, Sadik NA, Shaker OG, Aboultouf ML. Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochem Biophys 2013;67:875-84.
15. Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 2011;11:374.
16. Bianchi F, Nicassio F, Marzi M, Belloni E, Dallfolio V, Bernard L, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011;3:495-503.
17. Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 2014;32:768-73.
18. Shen J, Liao J, Guarnera MA, Fang H, Cai L, Stass SA, et al. Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis. J Thorac Oncol 2014;9:33-40.